Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24177719 | 0.84 | ALDH1A1 (0.52) | ALDH1A1ATMSMN1; SMN2EPHX2L3MBTL1 | |
| SCHEMBL6898986 | 0.83 | PSMB1 (0.45) | KMT2AMEN1KDM4EHPGD | |
| SCHEMBL4184236 | 0.81 | ALDH1A1 (0.56) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL20305268 | 0.81 | ALDH1A1 (0.59) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL2734500 | 0.80 | ATM (0.50) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL24157410 | 0.80 | ALDH1A1 (0.50) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL9281457 | 0.80 | ALDH1A1 (0.57) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL501897 | 0.79 | ALDH1A1 (0.58) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL10989633 | 0.79 | ALDH1A1 (0.54) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL146725 | 0.79 | ALDH1A1 (0.54) | ALDH1A1ATMSMN1; SMN2L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8350027-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7956054-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | ALDH1A1 2422/4885ATM 4493/4885SMN1; SMN2 4456/4885 |
| US-20130267497-A1 | KINASE INHIBITORS | PTK2, MAP3K6, MAP3K20 | ALDH1A1 2605/4885ATM 753/4885SMN1; SMN2 4781/4885 |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | ALDH1A1 2422/4885ATM 4493/4885SMN1; SMN2 4456/4885 |
| US-20090286773-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | ALDH1A1 2605/4885ATM 753/4885SMN1; SMN2 4781/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885ATM 562/4885SMN1; SMN2 4718/4885 |
| US-20120238558-A9 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | ALDH1A1 2605/4885ATM 753/4885SMN1; SMN2 4781/4885 |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ALDH1A1 2397/4885ATM 4412/4885SMN1; SMN2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.